This beneficial effect cannot be explained by amelioration of hyperglycemia or systemic inflammation, as blood glucose levels and serum MCP-1 were not changed by treatment, but is closely associated to the efficient renal NF-κB inhibition provided by the drug. The gene discussed is CCL2; the disease is Hyperglycemia.